Black Diamond Therapeutics Inc.

06/12/2025 | Press release | Distributed by Public on 06/12/2025 14:21

Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 12, 2025, Black Diamond Therapeutics, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting") in a virtual-only format via live webcast. Proxies were solicited pursuant to the Company's definitive proxy statement (the "Proxy Statement") filed on April 18, 2025 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. As of the close of business on April 14, 2025, the record date for the Annual Meeting, the number of shares of the Company's common stock, $0.0001 par value per share ("Common Stock"), outstanding and entitled to vote at the Annual Meeting was 56,676,716. The number of shares of Common Stock present in person or by remote communication, if applicable, or represented by valid proxy at the Annual Meeting was 42,988,581, thus establishing a quorum for the transaction of business at the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common Stock represented in person at the Annual Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company's stockholders at the Annual Meeting.

At the Annual Meeting, the Company's stockholders were asked to vote on the following matters, which were described in detail in the Proxy Statement: (i) to elect three Class II director nominees to the Company's Board of Directors (the "Board"), each to serve for a three-year term until the Company's 2028 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal ("Proposal No. 1") and (ii) to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 ("Proposal No. 2").

The voting results reported below are final.

Proposal No. 1

Ali Behbahani, Garry E. Menzel and Samarth Kulkarni were duly elected to the Board as Class II directors. The results of the stockholders' vote with respect to the election of the Class II directors were as follows:

CLASS II DIRECTOR NOMINEE FOR WITHHELD BROKER
NON-
VOTES
Ali Behbahani 14,529,061 19,960,856 8,498,664
Garry E. Menzel 33,533,241 956,676 8,498,664
Samarth Kulkarni 14,217,936 20,271,981 8,498,664

Proposal No. 2

The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. The results of the stockholders' vote with respect to such ratification were as follows:

FOR AGAINST ABSTAIN
42,483,483 445,873 59,225

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

Black Diamond Therapeutics Inc. published this content on June 12, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 12, 2025 at 20:21 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io